Loading...
Publication
COVID-19 research in critical care: the good, the bad, and the ugly
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 566.82 KB | Adobe PDF |
Advisor(s)
Abstract(s)
The extraordinary pace of research on coronavirus disease
2019 (COVID-19) has been one of the major success
stories of the pandemic. Therapeutic trials involving
thousands of patients, which usually take years to complete,
have been reported in a matter of months. National
and international registries and networks have reported
on tens of thousands of patients in near real time. However,
there have also been many challenges: hundreds of
trials have been underpowered, duplicated, or of poor
quality; excessive bureaucracy has complicated study initiation;
and only a small percentage of eligible patients
worldwide have been enrolled in studies, while many
others have been treated with off-label, unproven therapies.
All of this has been complicated by an “infodemic”
of low-quality medical information, accelerated by social
media.
Description
Keywords
COVID-19 Coronavirus
Citation
Publisher
Springer